Comparison Between Alpha Blocker Monotherapy and 5-alpha-reductase Inhibitor Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Alpha adrenergic receptor antagonists; Cholestenone 5-alpha reductase inhibitors
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- 02 Dec 2019 Biomarkers information updated
- 29 May 2013 Planned End Date changed from 1 Feb 2012 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 02 Mar 2011 New trial record